These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Erythropoiesis-stimulating agents--time for a reevaluation. Unger EF; Thompson AM; Blank MJ; Temple R N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037 [No Abstract] [Full Text] [Related]
4. The FDA black box for EPO: what should nephrologists do? Singh AK Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125 [No Abstract] [Full Text] [Related]
6. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. Steensma DP J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668 [No Abstract] [Full Text] [Related]
8. Clarifying the use of erythropoietic agents. Smith RE J Support Oncol; 2004; 2(3):200, 202; author reply 202. PubMed ID: 15328822 [No Abstract] [Full Text] [Related]
9. The FDA, stocks, black boxes and ESAs. Spry L Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124 [No Abstract] [Full Text] [Related]
10. Is normalising haemoglobin in patients with CKD harmful and if so, why? Littlewood TJ J Ren Care; 2009 Dec; 35 Suppl 2():25-8. PubMed ID: 19891682 [TBL] [Abstract][Full Text] [Related]
12. Erythropoietin: the swinging pendulum. Oster HS; Neumann D; Hoffman M; Mittelman M Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365 [TBL] [Abstract][Full Text] [Related]
13. Safety concerns for two big anemia drugs. Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980 [No Abstract] [Full Text] [Related]
14. [The results of the TREAT study: lessons and limitations]. Del Vecchio L G Ital Nefrol; 2010; 27(1):3. PubMed ID: 20191449 [No Abstract] [Full Text] [Related]
15. Use of erythropoietins in patients with renal transplants. Treleaven DJ; Clase CM BMJ; 2009 Oct; 339():b3825. PubMed ID: 19854838 [No Abstract] [Full Text] [Related]
16. Triumph and tragedy: anemia management in chronic kidney disease. Novak JE; Szczech LA Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350 [TBL] [Abstract][Full Text] [Related]
17. Full results on risks of epoetin emerge 14 years after major dialysis study. Epstein K BMJ; 2012 May; 344():e3535. PubMed ID: 22619221 [No Abstract] [Full Text] [Related]
18. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Dicato M Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z; Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464 [TBL] [Abstract][Full Text] [Related]
20. Anemia therapy in ESRD: time to move on. Folkert VW; Meyer TW; Hostetter TH Clin J Am Soc Nephrol; 2010 Jul; 5(7):1163-4. PubMed ID: 20538832 [No Abstract] [Full Text] [Related] [Next] [New Search]